Radiotherapy for Glioblastoma in the Elderly

Лучевая терапия при глиобластоме у пожилых пациентов
Florence Keime-Guibert, Olivier Louis Chinot, Luc Taillandier, Stéphanie Cartalat‐Carel, Marc Frénay, Guy Kantor, Jean‐Sébastien Guillamo, Eric Jadaud, Philippe Colin, Pierre‐Yves Bondiau, Philippe Meneï, Hugues Loiseau, V. Bernier, Jérôme Honnorat, Maryline Barrié, Karima Mokhtari, Jean‐Jacques Mazeron, Anne Bissery, Jean‐Yves Delattre
2007-04-11

elderly patientsglioblastomaoverall survivalradiotherapysupportive care
BACKGROUND: There is no community standard for the treatment of glioblastoma in patients 70 years of age or older. We conducted a randomized trial that compared radiotherapy and supportive care with supportive care alone in such patients. METHODS: Patients 70 years of age or older with a newly diagnosed anaplastic astrocytoma or glioblastoma and a Karnofsky performance score of 70 or higher were randomly assigned to receive supportive care only or supportive care plus radiotherapy (focal radiation in daily fractions of 1.8 Gy given 5 days per week, for a total dose of 50 Gy). The primary end point was overall survival; secondary end points were progression-free survival, tolerance of radiotherapy, health-related quality of life, and cognition. RESULTS: We randomly assigned 85 patients from 10 centers to receive either radiotherapy and supportive care or supportive care alone. The trial was discontinued at the first interim analysis, which showed that with a preset boundary of efficacy, radiotherapy and supportive care were superior to supportive care alone. A final analysis was carried out for the 81 patients with glioblastoma (median age, 73 years; range, 70 to 85). At a median follow-up of 21 weeks, the median survival for the 39 patients who received radiotherapy plus supportive care was 29.1 weeks, as compared with 16.9 weeks for the 42 patients who received supportive care alone. The hazard ratio for death in the radiotherapy group was 0.47 (95% confidence interval, 0.29 to 0.76; P=0.002). There were no severe adverse events related to radiotherapy. The results of quality-of-life and cognitive evaluations over time did not differ significantly between the treatment groups. CONCLUSIONS: Radiotherapy results in a modest improvement in survival, without reducing the quality of life or cognition, in elderly patients with glioblastoma. (ClinicalTrials.gov number, NCT00430911 [ClinicalTrials.gov].).
1
A randomized trial evaluated focal radiotherapy plus supportive care versus supportive care alone in glioblastoma patients aged 70 years or older.
2
Median survival was 29.1 weeks with radiotherapy versus 16.9 weeks with supportive care alone.
3
Radiotherapy caused no severe treatment-related adverse events and did not significantly worsen quality of life or cognition.
4
Radiotherapy reduced the risk of death by 53% (hazard ratio, 0.47; 95% CI, 0.29–0.76; P=0.002).
5
The trial stopped early because radiotherapy plus supportive care crossed the prespecified efficacy boundary for superiority.

elderly patients with newly diagnosed glioblastoma

the effects of radiotherapy plus supportive care versus supportive care alone on overall survival, progression-free survival, treatment tolerance, health-related quality of life, and cognition

Publication Details
Publication Date
2007-04-11
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Florence Keime-Guibert
Olivier Louis Chinot
Luc Taillandier
Stéphanie Cartalat‐Carel
Marc Frénay
Guy Kantor
Jean‐Sébastien Guillamo
Eric Jadaud
Philippe Colin
Pierre‐Yves Bondiau
Philippe Meneï
Hugues Loiseau
V. Bernier
Jérôme Honnorat
Maryline Barrié
Karima Mokhtari
Jean‐Jacques Mazeron
Anne Bissery
Jean‐Yves Delattre
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%